News & Topics
News&Topics

2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2023.05.29
IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial
2023.05.10
Onconova Therapeutics announces presentation of an overview of its investigator-sponsored clinical program evaluating rigosertib monotherapy in RDEB-associated SCC at the ISID International Epidermolysis Bullosa Symposium in Osaka
2023.04.27
Analyst Report[Flash report] (Shared Research)
2023.04.27
Summary of Consolidated Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
2023.04.24
SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease
2023.04.14
Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Directors
2023.04.14
Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
2023.03.24
Notice of Shareholder Voting Results for the 18th Annual General Meeting of Shareholders
2023.03.23
Notice of Appointments to the Board of Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
2023.03.23
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2023.03.23
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2023.03.22
Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)
2023.03.01
Information on Shareholders' Meeting: Updated the Page
2023.02.22
Notification of Amendment to the Articles of Incorporation
2023.02.09
Analyst Report[Flash report] (Shared Research)
2023.02.09
Summary of Financial Statements for the Fiscal Year Ended December 31, 2022 [Japanese GAAP] (Consolidated)
2023.02.09
Notice concerning non-operating expenses
2023.01.23
Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2023.01.16
Analyst Report[Follow-up Report] (Fair Research)
News & Topics